Clinical Trials Logo

Filter by:
NCT ID: NCT06325709 Recruiting - Clinical trials for Chronic Granulomatous Disease (CGD)

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Start date: April 17, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Chronic granulomatous disease (CGD) is a rare immune disorder caused by a mutation in the CYBB gene. People with CGD have white blood cells that do not work properly. This places them at risk of developing infections that may be life-threatening. Stem cell transplant can cure CGD but transplanting stem cells donated by other people can have serious complications. In addition, not everyone has a matched donor. Another approach is a type of gene therapy that involves base-editing to correct the mutation in a person s own stem cells. Researchers want to know if the base-edited stem cells can improve the white cells' functioning and result in fewer CGD-related infections. Objective: To learn if base-edited stem cells will improve white blood cells' ability to fight against infections in people with CGD. Eligibility: Males aged 18 years and older with X-linked CGD. Design: This is a non-randomized study. Participants with the specific mutation under study will be screened during the initial phase. During the development phase, participants will undergo apheresis to collect stem cells for base-editing correction of the mutation. During the treatment phase, participants will receive the base-edited cells after chemotherapy with busulfan. Participants will remain in the hospital until their immunity recovers. Follow-up visits will continue for 15 years.

NCT ID: NCT06325644 Recruiting - Clinical trials for Polycystic Kidney Disease

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD. This determined by combination of features of ADPKD and htTKV as assessed by prior computed tomography (CT) or MRI. Patients will be recruited from the Polycystic Kidney Disease (PKD) Clinic at Ohio State University Wexner Medical Center. Enrolled patients will have MRI for htTKV, urinary studies, blood tests at baseline, 6 months, and 52 weeks. Blood for GFR will be assessed three times over the course of the study including baseline, 6 months, and 1 year. Participants will follow ketogenic diet for 52 weeks. Investigatory diet team will manage the ketogenic diet.

NCT ID: NCT06325397 Recruiting - Nuclear Cataract Clinical Trials

Less Discomfort and Less Pharmacology. Cataract Surgery at Physiologic Intraocular Pressure (IOP)

Start date: October 23, 2023
Phase:
Study type: Observational

To investigate the impact of high vs low Intraocular Pressure (IOP) on the intraoperative experience for the patient and surgeon. Operating at a more physiologic IOP using Active Sentry hand piece during cataract surgery will result in significantly less discomfort/pain as assessed by the decreased need for rescue medication

NCT ID: NCT06325332 Recruiting - Clinical trials for Respiratory Syncytial Virus

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

BEAR
Start date: April 1, 2024
Phase:
Study type: Observational

The primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters. the secondary objectives are: 1. To estimate the effectiveness of nirsevimab against medical encounters with a respiratory related diagnosis. 2. To estimate the effectiveness of nirsevimab against medical encounters with an LRTD diagnosis. 3. To estimate the impact of nirsevimab on PCR-confirmed RSV. 4. To estimate the impact of nirsevimab on medical encounters with an otitis media diagnosis. 5. To estimate the impact of nirsevimab on antibiotic prescription.

NCT ID: NCT06325150 Recruiting - Healthy Clinical Trials

The Impact of Light Exposure on Cognitive Function in Classrooms

Start date: May 16, 2024
Phase: Phase 1
Study type: Interventional

Humans are constantly exposed to a variety of light types, created naturally or through artificial means. Light exposure captured by the eyes impacts many physiological functions in humans, including but not limited to cognitive output, fatigue levels, and mood regulation. The level of impact on cognitive learning from different types of light on undergraduate adult students remains unclear.

NCT ID: NCT06324981 Recruiting - Clinical trials for Cardiovascular Diseases

Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors

Start date: February 26, 2024
Phase: N/A
Study type: Interventional

The goal of our pragmatic clinical trial is to compare how well three different strategies might do to reduce risk factors for cardiovascular disease in patients experiencing health disparities. The three different strategies are: 1) text messages, 2) interactive chatbot messages, and 3) chatbot messages with proactive pharmacist support. To measure cardiovascular risk factors, the investigators are using the American Heart Association's Life's Essential 8 (LE8) factors-blood glucose, cholesterol, blood pressure, physical activity, body mass index, diet, and smoking. This study focuses on improving cardiovascular risk factors for individuals facing health disparities, such as ethnic minorities, limited English proficiency, and low-income groups. These groups are more likely to be seriously affected by cardiovascular diseases. Self-management, or an individual's roles in managing their own chronic disease, includes lifestyle changes, medication adherence. Improving patients' self-management has been shown to improve health behaviors, better disease control and improved patient outcomes. The main question this study aims to answer is if one of the strategies (texting, chatbot, or chatbot with pharmacist support) may improve patient self-management and patient outcomes. The investigators will enroll up to 2,100 patients from three health systems that serve large populations experiencing health disparities: Denver Health, Salud Family Health Centers, and STRIDE Community Health Center. The results might help researchers and health care systems find the best ways to involve patients with health disparities to managing their chronic cardiovascular disease.

NCT ID: NCT06324929 Recruiting - Sexual Behavior Clinical Trials

Optimizing a Digital AEP Risk Intervention With Native Women and Communities Aim 1

CARRII Native
Start date: May 16, 2024
Phase: N/A
Study type: Interventional

The purpose of this aim of the study is to gather quantitative and qualitative information to inform the development of a digital app tailored for Native American women to help them avoid a pregnancy affected by alcohol.

NCT ID: NCT06324786 Recruiting - Multiple Drug Use Clinical Trials

Brain Mechanisms of Reducing Polysubstance Use

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.

NCT ID: NCT06324435 Recruiting - Clinical trials for Alcohol Use Disorder

Apremilast for Alcohol Use Disorder Treatment in Women and Men

Start date: May 8, 2024
Phase: Phase 1
Study type: Interventional

For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).

NCT ID: NCT06324396 Recruiting - Fontan Circulation Clinical Trials

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

IMPROVE-FALD
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.